New cancer clinical trial: Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Published on: October 30, 2018 at 11:00PM
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3;   Elevated CEA;   Elevated Serum CA 27-29 Tumor Antigen Levels;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting
https://ift.tt/2Q61A28 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer